Cantor Fitzgerald Comments on ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Esperion Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biopharmaceutical company will post earnings of $0.05 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.28) per share.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The business had revenue of $51.63 million for the quarter, compared to analysts’ expectations of $55.44 million. During the same quarter last year, the business posted ($0.37) EPS.

ESPR has been the subject of several other research reports. StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $7.30.

Esperion Therapeutics Stock Up 2.3 %

Shares of Esperion Therapeutics stock opened at $2.20 on Wednesday. Esperion Therapeutics has a 12-month low of $1.58 and a 12-month high of $3.94. The firm has a market capitalization of $433.49 million, a PE ratio of -3.44 and a beta of 1.03. The stock’s fifty day moving average is $2.46 and its 200-day moving average is $2.18.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Public Employees Retirement System of Ohio bought a new stake in shares of Esperion Therapeutics in the third quarter valued at about $606,000. Anson Funds Management LP acquired a new stake in Esperion Therapeutics during the third quarter valued at approximately $540,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Esperion Therapeutics by 71.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 295,378 shares during the period. Wellington Management Group LLP grew its stake in shares of Esperion Therapeutics by 66.8% in the 3rd quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after purchasing an additional 241,512 shares during the period. Finally, Wasatch Advisors LP raised its holdings in shares of Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.